Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants and young children. In April 2024, the Korea Ministry of Food and Drug Safety approved nirsevimab (Beyfortus), a long-acting monoclonal antibody, as a passive immunization to prevent R...

Description complète

Détails bibliographiques

Auteurs principaux:	Soo-Han Choi, Dong Hyun Kim, Jong Gyun Ahn, Ki Wook Yun, Byung-Wook Eun, Jin Lee, Jina Lee, Taek-Jin Lee, Hyunju Lee, Dae Sun Jo, Eun Young Cho, Hye-Kyung Cho, Young June Choe, Ui Yoon Choi, Yun-Kyung Kim, The Committee on Infectious Diseases of the Korean Pediatric Society
Format:	Artigo
Langue:	Inglês
Publié:	The Korean Pediatric Society 2025-10-01
Collection:	Clinical and Experimental Pediatrics
Sujets:	respiratory syncytial viruses immunization monoclonal antibodies long-acting monoclonal antibodies
Accès en ligne:	http://e-cep.org/upload/pdf/cep-2025-01067.pdf
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!